98%
921
2 minutes
20
serogroup O25b-sequence type 131 ( O25b/ST131) is known as a multidrug-resistant organism with high virulence potential and has received attention internationally. We aim to investigate the prevalence of O25b/ST131 and the distribution of , pathogenicity island (PAI) markers, phylogenetic groups, and H-antigen typing in the O25b/ST131 isolated from patients with urinary tract infection (UTI) in Tehran, the capital of Iran. Seventy (26.9%) isolates were identified as O25b/ST131. There was also a significant difference in the prevalence of virulence genes, including , , , , , , and , in the O25b/ST131 isolates rather than non-O25b/ST131 ones ( 0.05). Furthermore, 78% of the O25b/ST131 isolates carried four to seven PAIs, while 71% of non-O25b/ST131 isolates carried two to four PAI markers ( 0.05). Our study showed that in addition to H4, other H-antigens may play a role in the O25b/ST131 virulence potential. Besides, a significant association was found between the history of previous UTIs and infection among the O25b/ST131 clone isolates. Pulsed-field gel electrophoresis revealed circulating of O25b:H4-ST131/PST43 clone in both hospital and community. Approximately one in every three uropathogenic isolates was the O25b/ST131 clone, representing a significant public health threat. Practical investigation on O25b/ST131 can be helpful in better understanding of ST131 evolution and controlling UTI in hospitals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/mdr.2019.0485 | DOI Listing |
PeerJ
May 2025
Department of Basic Medical Sciences, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq.
Background: Isolation of family of extended-spectrum beta-lactamases (ESBL) is a challenge in the field of microbiology in our locality that makes treatment fail and disseminate quickly.
Objectives: To determine the prevalence of ESBL gene in clone O25B-ST131 isolated from COVID-19 patients with different infections.
Methods: This cross-sectional study was conducted on 528 patients hospitalized due to COVID-19 infection with various symptoms from April to September 2021.
J Infect Dev Ctries
December 2024
Instituto Nacional de Salud Pública (INSP), Centro de Investigación Sobre Enfermedades Infecciosas (CISEI), Departamento de Diagnóstico Epidemiológico. Cuernavaca, Morelos, México.
Introduction: Escherichia coli has emerged as an important pathogen in urinary tract infections (UTIs) due to the rapid acquisition of antibiotic resistance genes. This enhances the ability of E. coli to colonize and creates therapeutic challenges within the healthcare system.
View Article and Find Full Text PDFInfect Immun
October 2024
Pfizer Vaccine Research and Development, Pearl River, New York, USA.
The increase in urinary tract infections (UTI) caused by antibiotic-resistant requires the development of new therapeutic agents and prophylactic vaccines. To evaluate the efficacy of new lead candidates, we implemented a cynomolgus macaque UTI challenge model that mimics human uncomplicated cystitis in response to transurethral challenge with a multidrug-resistant (MDR) serotype O25b ST131 isolate. fimbrial adhesin FimH and O-antigens are separately under clinical evaluation by others as vaccine candidates to prevent UTI and invasive urosepsis disease, respectively.
View Article and Find Full Text PDFJ Antimicrob Chemother
September 2024
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Objectives: Escherichia coli can cause infections in the urinary tract and in normally sterile body sites leading to invasive E. coli disease (IED), including bacteraemia and sepsis, with older populations at increased risk. We aimed to estimate the theoretical coverage rate by the ExPEC4V and 9V vaccine candidates.
View Article and Find Full Text PDFMikrobiyol Bul
October 2023
Ankara University Faculty of Medicine, Department of Medical Microbiology, Ankara, Türkiye.